AC Immune (NASDAQ:ACIU) Downgraded by StockNews.com

StockNews.com lowered shares of AC Immune (NASDAQ:ACIU) from a buy rating to a hold rating in a research note issued to investors on Tuesday.

Separately, HC Wainwright reaffirmed a buy rating and issued a $16.00 price objective on shares of AC Immune in a research note on Wednesday, September 18th.

AC Immune Price Performance

ACIU stock opened at $3.39 on Tuesday. The company has a fifty day moving average price of $3.44 and a two-hundred day moving average price of $3.39. AC Immune has a one year low of $2.20 and a one year high of $5.14. The stock has a market cap of $335.27 million, a price-to-earnings ratio of -4.91 and a beta of 1.24.

AC Immune (NASDAQ:ACIU) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.67). The company had revenue of $0.76 million during the quarter, compared to analyst estimates of $91.60 million. Research analysts anticipate that AC Immune will post -0.89 EPS for the current fiscal year.

Hedge Funds Weigh In On AC Immune

Institutional investors and hedge funds have recently modified their holdings of the business. Platinum Investment Management Ltd. lifted its holdings in shares of AC Immune by 14.6% in the 4th quarter. Platinum Investment Management Ltd. now owns 1,515,585 shares of the company’s stock worth $7,578,000 after purchasing an additional 193,123 shares in the last quarter. Avidity Partners Management LP increased its position in shares of AC Immune by 50.5% during the 4th quarter. Avidity Partners Management LP now owns 4,469,080 shares of the company’s stock valued at $22,345,000 after purchasing an additional 1,499,280 shares during the last quarter. BVF Inc. IL increased its position in shares of AC Immune by 96.2% during the 4th quarter. BVF Inc. IL now owns 14,571,236 shares of the company’s stock valued at $72,856,000 after purchasing an additional 7,142,857 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of AC Immune by 96.5% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,008 shares of the company’s stock valued at $56,000 after purchasing an additional 9,334 shares during the last quarter. Finally, BNP Paribas Financial Markets increased its position in shares of AC Immune by 315.6% during the 1st quarter. BNP Paribas Financial Markets now owns 11,092 shares of the company’s stock valued at $33,000 after purchasing an additional 8,423 shares during the last quarter. 51.36% of the stock is currently owned by institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.